COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04639375

John Andrews, PhD

johnclaytonandrews@gmail.com

2020-11-20

Not recruiting

nonRCT

Non-randomized

Single group assignment

Open label

single-center

Prevention

inclusion criteria: provision of signed and dated informed consent form stated willingness to comply with all study procedures and availability for the duration of the study male or female, aged 18-80 female subjects of child-bearing potential must have a negative pregnancy test (point-of-care dipstick) prior to being vaccinated and be willing to use an effective method of birth control from the time of entry into the study and for 30 days following vaccination in good general health with no active infectious disease as evidenced by medical history and directed physical examination.

known allergic reactions to components of the polio vaccine febrile illness within 14 days positive for sars-cov-2 antigenemia at any time prior to screening1 positive for sars-cov-2 antibodies at any time prior to screening1 subjects with fever > 101o f at screening subjects who respond yes to any of the following question: have you experienced any of the following symptoms in the past 48 hours (14): fever or chills cough shortness of breath or difficulty breathing fatigue muscle or body aches headache new loss of taste or smell sore throat congestion or runny nose nausea or vomiting diarrhea treatment with an investigational drug or other intervention within the 90 days prior to enrollment in this study inoculation with polio vaccine within the last 12 years women who are pregnant or breast feeding

1

E-MO Biology Inc

18

80

United States

Healthy volunteers

N/A

300

Percentage of Subjects with Antibodies to SARS-CoV-2 RdRp following IPV Vaccination

None

Phase 4

[{"arm_notes": "1", "treatment_id": 1007, "treatment_name": "Polio vaccine", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}]